Could BBT001 quarterly dosing differentiate Bambusa in the atopic dermatitis biologics market?
Bambusa’s BBT001 produced an early atopic dermatitis signal, but larger trials must confirm safety, durability and quarterly dosing.
Pharma & Biotech
Pharma & Biotech
AbbVie nears reported $10.9bn Apogee deal as zumilokibart heads toward Phase 3
AbbVie could pay a substantial premium for Apogee Therapeutics and its long-acting eczema antibody, but the reported deal depends on Phase 3 success and differentiation from established immunology drugs.
Pharma & Biotech
GSK’s Exdensur wins FDA nod for severe asthma: Can twice-yearly dosing reset the biologics playbook?
GSK’s Exdensur has been approved by the FDA as the first biannual biologic for severe asthma. Find out what this means for patients, payers, and rivals.